Baillie Gifford & Co
STOK icon

Baillie Gifford & Co’s Stoke Therapeutics STOK Stock Holding History

Baillie Gifford & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Buy
575,182
+328,282
+133% +$10.8M 0.02% 185
2025
Q4 		$7.84M Buy
+246,900
New +$7.42M 0.01% 224

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Baillie Gifford & Co's STOK Position: Q1 2026 in Review

Baillie Gifford & Co increased its Stoke Therapeutics (STOK) stake by 133% in Q1 2026, buying an estimated $10.8M and bringing the position to 575,182 shares worth $18.7M. The position accounts for 0.02% of the portfolio, ranked #185.

Baillie Gifford & Co first reported a position in STOK in Q4 2025 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Baillie Gifford & Co held 575,182 shares of Stoke Therapeutics worth $18.7M as of Q1 2026.
  • Baillie Gifford & Co bought 328,282 Stoke Therapeutics shares in Q1 2026, an estimated $10.8M.
  • Stoke Therapeutics made up 0.02% of Baillie Gifford & Co's portfolio in Q1 2026, its #185 holding.
  • Baillie Gifford & Co first reported a position in Stoke Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Baillie Gifford & Co's 13F filing for Q1 2026, filed 8 May 2026.